Canada: Confirmation Of The Patentability Of DNA/Gene Sequences In The United States

Last Updated: January 4 2012
Article by Andrea Pitts, Summer Student

Most Read Contributor in Canada, September 2016

Canadian courts showed promising support for DNA/gene patents by ruling in favour of Monsanto in its often-cited patent infringement case.1 Recent jurisprudence from the United States reaffirmed the patentability of some DNA/gene patents after a hotly debated District Court decision and its much anticipated Court of Appeal counterpart involving Myriad Genetics (Myriad).2

The Myriad cases show the importance of understanding complicated science when applying patent law. At issue was the validity of patents awarded to Myriad that covered (1) isolated DNA containing all or portions of the BRCA1 and BRCA2 gene sequence, (2) screening potential cancer therapeutics via changes in cell growth rates and (3) methods for comparing or analyzing their gene sequences in order to identify the presence of mutations correlating with a predisposition to breast or ovarian cancer.


The plaintiffs sought to obtain a declaration of invalidity on a patent issued by the US Patent and Trademark Office (USPTO) to Myriad. After years of research, investment and genetic engineering, Myriad had developed a chemical compound having a sequence of nucleotides which never before existed in nature. Specifically, Myriad isolated two breast cancer susceptibility genes, BRCA1 and BRCA2, and made a synthetic DNA probe that could be used in a detection assay to determine a patient's susceptibility to breast cancer due to mutations in these genes.

The District Court held that Myriad's claims were not patentable subject matter, as the claimed isolated DNA is not "markedly different" from native DNA "in light of DNA's unique qualities as a physical embodiment of information".3 Furthermore, the method claims were held not to be patentable as they were mental processes.

However, on appeal, the Court of Appeals for the Federal Circuit (CAFC) held that the District Court, in effect, created a rule categorically excluding isolated genes from patent eligibility. When the CAFC considered the applicable law, it held that such categorical exclusions were not warranted unless the legislature expressly stated such a limitation, which was not the case with respect to this subject matter.4 Thus, the CAFC reversed the District Court's ruling on Myriad's "composition" claims and in part on the "method" claims.


In Myriad, a proper understanding of the science was essential to a just application of patent law. The decision of the CAFC lays out a summary of the science behind isolated DNA and why it is patentable subject matter. Importantly, the CAFC recognized that isolated DNA is patent eligible as it has a "distinctive chemical identity and nature – from molecules that exist in nature".5 It was also recognized that unlike native DNA, which exists as part of a much larger structural complex, isolated DNA is free-standing and has been cleaved or synthesized resulting in a product that is a mere fraction of its native form.6 Specifically, the CAFC was persuaded that isolated BRCA1 and BRCA2, which lack introns, are not the same molecules that exist in the body.7

The CAFC used this scientific understanding when applying the United States Supreme Court's test for deciding whether a composition is patent eligible. In Funk Brothers, the United States Supreme Court (USSC) held that "works of nature" are not patent eligible subject matter.8 This decision was further elaborated in Chakrabarty, where the USSC held that in order for claimed subject matter to be patent eligible it should have "markedly different" characteristics than those found in nature.9

The CAFC in Myriad applied the Chakrabarty test to the composition claims covering isolated DNA. While the Court recognized the information coding capabilities of DNA, it acknowledged it as but one similarity between native DNA and its isolated form. Importantly, the Court held that this one similarity does not negate the many differences between native and isolated DNA. The Court recognized much fault in the part of the Plaintiff's argument that focused on the retention of the information coding capabilities in isolated DNA and ultimately concluded that isolated DNA was "markedly different" from its native constituent and, as a result, was eligible for patent protection. The CAFC also recognized that the longstanding practice of the USPTO to patent isolated DNA molecules should not be disturbed by the courts.10 In keeping with jurisprudence from the USSC, the CAFC recognized that if there was to be a change it should come from Congress itself.11

Regarding the method claims, the CAFC found all but one type valid. Specifically, Myriad claimed methods of "comparing" or "analyzing" BRCA sequences in order to identify whether a person is genetically susceptible to cancer. The Court relied on Benson,12 which held that basic tools of scientific work such as mental processes are not patent eligible as they are basic components of work in science and technology. The Court found that comparing and analyzing a sequence from a tumor sample is nothing more than a mental process and that comparing the two sequences requires nothing more than inspection, thus claims are patent ineligible.13

In terms of Myriad's claim to methods of screening potential cancer therapeutics, the Court recognized the inclusion of an important difference – transformative steps. The Court considered the ruling of the USSC in Bilski that stands for the presence of "transformative" steps being an "important clue" indicating patentability.14 The claim by Myriad involves "growing" host cells that contain an altered BRCA1 gene in an environment containing a potential cancer therapeutic, as well as determining their growth rate and comparing them to normal cells.15 The Court found that "growing" such transformed cells and "determining" growth rates is a method of transformation, requiring much more than just mental steps of comparison. Thus, it held that these claims were patent eligible.


The District Court's decision in Myriad represented a change in the longstanding practice of the USPTO in granting patents covering isolated DNA molecules. Had it been upheld by the CAFC, the results could have been disastrous for more than just the biotechnology sector, as they likely would have led to a decrease in investment, resulting in a further decrease in innovation.

Thousands of DNA/gene patents exist and help to promote innovation and investment through promoting healthcare and agriculture advancements. Without gene patents, companies all over the world could face multi-million dollar losses from loss of sales of products which were easily being copied by others. The CAFC's decision in Myriad makes a thorough and careful examination of the science and considers years of patent law. It is important that the courts in Canada make note of the CAFC's attention to scientific reasoning and of the longstanding practice of the Canadian Intellectual Property Office if issues such as the ones considered by the Court in Myriad come before them.


1 Monsanto Canada Inc v Schmeiser, 2004 SCC 34, 31 CPR (4th) 161 (SCC).

2 Association for Molecular Pathology et al v The United States Patent and Trademark Office et al, 702 F Supp (2d) 181 (SDNY 2010) [Myriad TD ]; rev'd Fed Cir, No 2010-1406 (29 July 2011) [Myriad CAFC ].

3 Myriad TD, ibid at 229.

4 Myriad CAFC, supra at 45.

5 Ibid at para 41.

6 Ibid at para 42.

7 Ibid at para 42.

8 Funk Brothers Seed Co v Kalo Inoculant Co, 333 US 127 (1948) at 130.

9 Diamond v Chakrabarty, 447 US 303 (1980) at 310.

10 Myriad CAFC, supra at para 47.

11 Ibid.

12 Gottschalk v Benson, 409 US 63 (1972) at 67.

13 Myriad CAFC, supra at para 50.

14 Bilski v Kappos, 130 S Ct 3218.

15 Myriad CAFC, supra at para 53.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.